BioWorld

Jan. 8, 2004

PTC To Fund Drug Development Through $35M Financing Round

PTC Therapeutics Inc. raised $35 million to support its initial clinical drug development activities and other product research. (BioWorld Today) Read More

Elan's Former Neurex Product, Prialt, Hits Phase III Endpoint

New Drug Efalizumab OK'd By FDA But Not As Definitive Cure; Psoriasis Still Plagues Legions

Thios Adds To Pipeline Through TS1 Licensing Deal With Wyeth

Forbes Medi-Tech Private Placement Raises $10.75M

Other News To Note

News in brief

BioWorld Asia

BioWorld Asia briefs for April 28, 2026

Chinese biotechs gain leverage as partners in dealmaking

BioWorld

China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...

AI generated image for researcher developing antisense oligonucleotides

Bio Korea 2026 kicks off with spotlight on oligonucleotides

BioWorld

Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...

Roche identifies new TREM2 agonists

BioWorld Science

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...

Plasticity, properly parsed, provides psychiatric platform

BioWorld

If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...